Targeted therapy with BRAF inhibitors (BRAFi) and MEK inhibitors (MEKi) provides rapid disease control with high response rates in patients with BRAF-mutant metastatic melanoma. However, the majority of patients develop resistance to therapy during the course of therapy. Immune checkpoint inhibitors show a slower onset of action with lower response rates, with responders showing sustained response. The combination of BRAFi/MEKi and immune checkpoint inhibitors combines the hope for a fast, reliable and lasting response to therapy. Preclinical data supports this hypothesis.
Introduction
Melanoma is a malignant tumor that arises from melanocytes, the pigment producing cells in the skin and other anatomic sites such as mucosa, uvea and leptomeninges [1] . Melanoma is the deadliest form of skin cancer, accounting for the vast majority of skin cancer related deaths [2, 3] . The incidence of melanoma is on the rise for the last decades [4] [5] [6] . First and best treatment for early melanomas is surgical removal. Until recently, only limited therapy options were available for advanced stage melanoma. Chemotherapy yields objective response rates in 5%-12% of patients with merely 1-2% of patients achieving durable responses [7] . High-dose interleukin-2 is only effective in a small, selective group of patients, with reported response (complete + partial response) and complete response rates of 16-18% and 7-8%, respectively [8] . Since 2011, this has changed drastically with the approval of new effective signal transduction targeted therapies (BRAFi and MEKi) and immunotherapies (anti-CTLA-4, anti-PD-L1 and anti-PD-1 antibodies). Both therapy strategies have changed the perspectives for patients, leading to 5-year survival rates of ≥ 30% [9, 10] .
Targeted therapies and immunotherapies are different in their mode of action. BRAFi and MEKi impair the signal transduction pathways that regulate proliferation and survival of melanoma cells. These inhibitors act very fast, often within days, and achieve high response rates with a disease control rate of 100% in patients harboring an activating mutation in the BRAF oncogene. For instance, with the combination of the BRAFi encorafenib and the MEKi binimetinib the median progression free survival is up to 14 months [11] . Especially patients with low lactate dehydrogenase (LDH) levels appear to have a significantly favorable outcome, as the 5-year survival rate for patients with low LDH levels and < 3 metastatic sites is 51% compared to 5% for patients with high LDH levels [10] .
Immunotherapies work by directing the attention of the immune system against the cancer to actively kill the tumor cells. Immune checkpoint inhibitors work by blocking the exhaustion signals on CD8 + T cells to keep them in action. Compared to targeted therapies, immune checkpoint inhibitors appear to act slower and achieve lower response rates. For instance, nivolumab alone or in combination with ipilimumab achieve response rates of 44 and 58%, respectively [12] . However, when patients respond to treatment, in the majority of patients the responses are durable. The 5-year survival rate for pembrolizumab for treatment-naive patients is 41% [9] . The 3-year overall survival rate for patients with normal LDH levels receiving ipilimumab and nivolumab or nivolumab monotherapy is 66% and 61%, compared to 44% and 34% for patients with increased LDH levels [13] .
Despite this enormous progress in therapy for advanced stage melanoma more effective treatment strategies are needed to overcome low response rates and resistance mechanisms. This requires a better understanding of the mode of action of the targeted therapies and immunotherapies, the anticancer immune responses and the immune escape mechanisms of the tumor. An effective cancer-immunity cycle [14] (graphical abstract), in which the cancer is recognized and eradicated through a series of events, is crucial for tumor control. As the tumor often interferes with the antitumor immune responses, treatment strategies to improve these responses are needed.
One strategy currently under investigation is combining targeted therapies and immunotherapies. This may not only combine the rapid and reliable response achieved by targeted therapy with the long-term clinical benefit of immune checkpoint inhibitor therapy, but may also be meaningful from an immunological perspective. Contrary to the original assumption that MAPK inhibition could have negative immunological effects through inhibiting the activity of immune cells, there is now increasing evidence of enhanced antitumor immunity using targeted drugs [15] . This could argue for a synergistic effect of targeted and immunotherapies, which could result in a higher response rate and a better quality of response with an increased progression-free and long-term survival. Accordingly, early data from clinical trials suggest that overall response rates of triple-combination therapies (BRAF, MEK and immunotherapy) are similar or even higher compared to combined BRAFi and MEKi. Results on duration of response and long-term survival are eagerly awaited.
In order to provide an immunological rationale for combining BRAFi/MEKi and immune checkpoint inhibitors in patients with advanced stage melanoma, this article reviews data on the immunological effects of BRAFi and MEKi.
BRAFi and MEKi do not have adverse effects on host immune cells in vivo
Given the central role of the MAPK pathway in T cell receptor signaling [16] including regulation of T cell expansion, differentiation and functions such as cytokine secretion and chemotaxis, concerns were initially raised regarding the effects of BRAFi/ MEKi on the immune system.
Evidence suggests that BRAFi do not appear to have major detrimental effects on lymphocytes. Comin-Anduix and colleagues demonstrated that therapeutical concentrations of the BRAFi vemurafenib do not affect the viability, proliferation, cytotoxicity and cytokine production of lymphocytes from melanoma patients or healthy donors [15] . A study of the BRAFi GSK2118436 (dabrafenib) confirmed that BRAFi do not affect the clinical parameters such as serum cytokine levels (including IFNγ, TNFα, IL-2, IL-6, IL-8, IL-10), peripheral blood cell counts and leukocyte subset frequencies [17] .
Instead, BRAF inhibition can cause paradoxical activation of the MAPK pathway, leading to activation of T cells and enhanced T cell function. In BRAF wild-type cells, BRAFi induce paradoxical activation of the MAPK pathway by a conformational change in the BRAF protein, which promotes dimerization and interaction with RAS. This results in the allosteric transactivation and phosphorylation of the RAF dimer partner, leading to downstream signaling and thus MAPK pathway hyperactivation [18] . Paradoxical activation of the MAPK pathway, as evidenced by increased phosphorylation of ERK, was induced with the BRAFi dabrafenib in mouse splenocytes [19] . Additionally, Callahan and colleagues demonstrated in vitro and in vivo that administration of a pan-RAF inhibitor increased phosphorylation of ERK in both CD4 + and CD8 + T cells [20] .
Several in vitro studies showed that in comparison to BRAFi, MEKi can negatively influence T cell function. MEKi alone or in combination with BRAFi suppressed T-lymphocyte proliferation and their cytokine production [21] [22] [23] [24] . For instance, clinically relevant levels of trametinib caused a partial inhibition of CD4 + T cell proliferation after 3 days, which, however, did not persist after 7 days of treatment [22] . Moreover, inhibition of CD4 + T cell proliferation was not observed when T cells were activated with CD3/CD28 antibodies before adding trametinib. Interestingly, Hu-Lieskovan and colleagues demonstrated that the MEKi trametinib interferes with effector T cell function in vitro, but not in vivo [19] . In a pmel-1 adoptive cell transfer (ACT) mouse model, the addition of trametinib to dabrafenib did neither change the lytic activity of the adoptively transferred T cells (ATCs) against the tumor cells such as T cell infiltration and cytotoxicity, nor their ability to respond to gp100 stimulation with IFNγ release.
Ebert et al. also analyzed the effects of MEKi on different T cell stages in mice [24] . Although MEKi blocked naïve CD8 + T cells priming in the lymph node, it increased antigen-specific CD8 + T cells within the tumor. The tumor-infiltrating T cells expressed T-bet (Tbx21) and Eomes (eomesodermin), transcription factors that are important for T cell differentiation and cytotoxic activity [25] . In addition, MEKi protected these T cells from death caused by chronic T cell-receptor (TCR) stimulation, in that it prevented the up-regulation of Nur77 and activation of caspases downstream of TCR signaling [24] . In summary, BRAFi appear to have an activating effect on immune cells through the paradoxical activation of the MAPK signaling pathway. MEKi, on the other hand, seem to suppress T cell functions in vitro, but do not appear to have relevant effects on T cell functions in vivo.
BRAF-mutant tumors induce immune escape mechanisms
A number of studies suggested that BRAF-mutant tumors establish different immune escape mechanisms, leading to the development of an immunologically "cold" tumor that evades effective T-cell responses. Interference with T cell activation can occur at different stages of the cancer-immunity cycle [14] (graphical abstract).
Firstly, BRAF-mutant tumors may create an immunosuppressive microenvironment that prevents tumor antigen presentation by antigen-presenting cells (APCs) such as dendritic cells (DCs) and macrophages and subsequent T cell priming. Ho et al. found that during development of BRAF-mutant tumors expression of IFNγ, TNFα and IL-2 as well as CD40L on CD4 + tumor-infiltrating lymphocytes (TILs) was reduced [26] . CD40:CD40L signaling and IFNγ are critical immunologic factors that can enhance maturation of DCs, help to boost CD8 + T cell activation and expansion, and polarize M1-like macrophages [27] . In accordance with this, Ho et al. demonstrated that in macrophages the expression of M1-like cytokines (including IL-1β, IL-12) was decreased, while expression of M2-like genes (including Mrc1, Arg1, MMP9) was increased [26] . In general, M1-like macrophages produce IL-12 and promote Th1-differentiation, while M2-like macrophages dampen immune responses by producing IL-10 and VEGF [28] . Moreover, the tumor infiltrating dendritic cells (TIDS) isolated from advanced BRAFV600E/PTEN-driven melanomas could not stimulate proliferation of gp100-specific (Pmel) CD8 + T cells anymore [26] . Ott et al. and
Sumimoto et al. could also show that in vitro BRAFV600E melanoma cells affected maturation of DCs and suppressed their capacity to produce IL-12 and TNFα [29, 30] . BRAF-mutant tumors may also interfere with later stages of the cancer-immunity cycle [14] , such as recognition of the tumor cells by effector T cells before killing their target. T cells can only recognize antigens with their T cell receptor (TCR) when presented to them via human leukocyte antigen (HLA) class I molecules on the surface of tumor cells [31] . The MAPK pathway has been shown to be a predominant regulator of HLA class I expression. Bradley et al. demonstrated that BRAF-mutant tumors downregulate HLA class I molecules on their cell surface through internalization and intracellular sequestration [32] .
Furthermore, there is evidence that BRAF-mutant melanomas may create a microenvironment that is inhibitory to T cell effector functions. For instance, Ho et al. could demonstrate in a BRAFV600E/PTENdriven murine model of melanoma, that developing tumors induced accumulation of regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) [26] . Tregs limit responses of effector T cell populations by cell-cell contact-dependent mechanisms and immunosuppressive cytokines. MDSCs are a heterogeneous population of cells that are defined by their myeloid origin and ability to potently suppress T cell responses (for a detailed review on Tregs and MDSCs and their role in cancer, see [33] [34] [35] ). In agreement with these findings, Sumimoto and colleagues could show that BRAFV600E melanoma cells had an increased expression of immunomodulatory cytokines like IL-6 and IL-10 [30] , which are molecules that can promote recruitment of immunosuppressive cells such as MDSCs and Tregs to the tumor microenvironment.
Altogether, these results demonstrate that constitutive upregulation of the MAPK signaling pathway by a BRAF mutation can lead to a protumorigenic microenvironment with an ineffective antitumor immune response. This indicates that BRAF and MEK inhibition may reverse the immunosuppressive effects and create an immunologically "hot" tumor.
Immunological effects of BRAF and MEK inhibition
Although BRAFi and MEKi were not designed to directly stimulate antitumor immune responses, there is increasing evidence of enhanced antitumor immunity with use of these drugs.
Promotion of an immune stimulatory microenvironment
As mentioned in section 3, melanoma may generate ineffective antitumor T cell responses by creating an immunosuppressive microenvironment and thereby interfering with different stages of the cancerimmunity cycle [14] , such as antigen presentation and recognition of cancer cells. Several in vitro and in vivo studies have shown that the administration of BRAFi and MEKi could restore the immune stimulatory microenvironment in BRAF-mutant tumors by increasing the expression of immune stimulatory and decreasing the expression of immunosuppressive molecules as well as reducing the number of regulatory immune cells such as Tregs and MDSCs.
Ho and colleagues could demonstrate in a BRAFV600E/PTENdriven murine model of melanoma that BRAFi increased CD40L and IFNγ expression of intratumoral CD4 + TILs and also reduced accumulation of Tregs and MDSCs [26] . Interestingly, blocking either CD40L or IFNγ impaired the ability of BRAFi to inhibit melanoma growth. Furthermore, BRAFi also induced upregulation of major histocompatibility complex (MHC) class I and CD70 molecules (indicating the activation and maturation status) on APCs in a CD40L-and IFNγ-dependent manner.
In a co-culture of monocyte-derived human DCs with melanoma cells, DCs displayed reduced expression of the cytokines IL-12 and TNFα and surface markers CD80, CD83, and CD86 [29] , latter of which can stimulate the activation and survival of T cells. This effect was reversed by BRAFi or BRAFi combined with MEKi in BRAF-mutant melanoma cells.
Several studies could demonstrate that in BRAF-mutant cells BRAFi treatment alone or in combination with MEKi caused a reduction in the expression of immunosuppressive molecules such as IL-1 A, IL-6, IL-8, IL-10 and VEGF, thereby counteracting the tumor-induced immune escape mechanisms [22, 30, 36] . Accordingly, in melanoma patients administration of BRAFi or BRAFi combined with MEKi led to a more favorable tumor microenvironment, as evidenced by a decrease of the immunosuppressive cytokines IL-6 and IL-8 [37] .
The CC-chemokine ligand 2 (CCL2) has been reported to promote cancer cell proliferation, invasion, migration, and survival via binding to its functional receptor CCR2 [38] . In a mouse model of BRAFV600E melanoma, the BRAFi vemurafenib decreased the expression of CCL2 in melanoma cells, which was associated with tumor growth reduction. Reduced tumor growth was also associated with higher NK cell infiltrates and an increased ratio of CD8 + T cells to Tregs within the tumor [39] . In addition, Steinberg et al. demonstrated that BRAF inhibition decreases the proportions of Tregs and MDSCs in a BRAF/PTEN-inducible autochthonous melanoma mouse model [40] . In contrast, Treg proportions were unchanged in the BRAF/PTEN tumor-draining lymph nodes and in BRAF wild-type B16 tumors, demonstrating that this was an on-target effect localized to the tumor microenvironment. In line with these findings, in melanoma patients the BRAFi vemurafenib was shown to reduce the amount of MDSCs in blood samples [41] .
Interestingly, there is evidence that inhibition of the MAPK signaling pathway by MEKi in BRAF wild-type melanoma may also lead to an increased immune stimulatory microenvironment. In a mouse model using mice bearing KRAS-driven breast tumors, the MEKi trametinib was shown to abrogate the mobilization of MDSCs into tumors by reducing tumor-secreted chemotactic molecules like osteopontin and by decreasing the mobilization and differentiation of bone marrow MDSC precursors [42] .
In summary (Table 1) , these results indicate that BRAFi and MEKi in BRAF-mutant melanoma as well as MEKi in BRAF wild-type melanoma could lead to an immune stimulatory microenvironment by enhancing expression of immune stimulatory molecules and cytokines, reducing immunosuppressive cell populations, and decreasing immunosuppressive cytokines.
Increased T cell infiltration into the tumor microenvironment
Infiltration of cytotoxic T cells into the tumor bed is an essential step in the anticancer immune response. A number of studies demonstrated that treatment with BRAFi +/-MEKi is associated with an increased CD8 + T cell infiltration into the tumor microenvironment [37, [43] [44] [45] .
In an in vivo model, BRAFi significantly enhanced the activity and increased the infiltration of ATCs into human BRAF-mutant melanoma [44, 46] . Increased T cell infiltration could be attributed to a loss of VEGF expression. VEGF is a key angiogenic factor known to stimulate ↑ [37] improved activity of immune effector cells in vitro reactivity of T lymphocytes ↑ (measured by IFNɣ release) [21, 26] in vivo T cell cytotoxicity ↑ (perforin, granzyme B) [37] ↑ (perforin, granzyme B) [37] i.a.: inter alia;
↑ increased ↓ reduced → no effect.
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endothelial cell survival and growth. High levels of VEGF lead to induction of vessel abnormalities that diminish drug delivery and influx of immune cells into tumors [47] . It was hypothesized that ERK inhibition by BRAFi caused a reduction of Myc expression and thus led to reduced binding of Myc to the VEGF promoter [44] . Interestingly, BRAFi increased infiltration of T cells only into BRAF-mutant but not into BRAF wild-type tumors. Reduced VEGF expression was also demonstrated by in vitro studies on BRAF-mutant cell lines treated with MEKi and BRAFi alone or in combination [30] . Consistent with the preclinical data, melanoma patient-derived biopsies before and during BRAFi treatment also demonstrated reduced VEGF expression during BRAFi therapy [44] . Increased T cell infiltration into the tumor and reduced VEGF expression was also demonstrated by studies on BRAF wild-type melanoma treated with MEKi [24, 36] .
Taken together (Table 1) , BRAFi and MEKi in BRAF-mutant and MEKi in BRAF wild-type melanoma may lead to increased T cell infiltration into the tumor microenvironment. This could be due to decreased VEGF expression.
Enhanced recognition of melanoma by T cells
As described in section 3, BRAF mutant melanoma can escape recognition by T cells through reducing HLA I expression on their cell surface. BRAFi and MEKi appear to counteract this, as treatment of BRAF-mutant melanoma with MEKi +/-BRAFi led to increased expression of HLA class I and/or HLA class II molecules on the tumor cell surface [22, 48] . In accordance with these findings, activated MAPK signaling suppressed components of HLA class I and the antigen presentation machinery in different mouse tumor models, which was reversed by MAPK pathway inhibition [32, 48] .
Additionally, in vitro and in vivo studies showed that BRAFi +/-MEKi treatment increases expression of the melanoma differentiation antigens MART-1 (Melanoma Antigen Recognized by T cells), gp100 (Glycoprotein 100), TYRP1 (Tyrosinase related protein 1) and DCT (Dopachrome Tautomerase). This led to an enhanced recognition of the tumor by T cells [21, 37] .
Interestingly, these effects occurred not only in BRAF-mutant melanoma but also in BRAF wild-type melanoma treated with MEKi, as treatment with MEKi also increased expression of HLA I and/or II [22] and melanoma antigens in BRAF wild-type melanoma cells [21, 22] .
To sum up (Table 1) , these results indicate that BRAFi and MEKi in BRAF-mutant and MEKi in BRAF wild-type melanoma enhance the recognition of melanoma cells by the immune system by increasing melanoma antigen expression and expression of HLA I and/or HLA II.
Improved activity of T cells
Killing of the cancer cell by cytotoxic T cells is the final and most decisive step in the anticancer immune response [14] , which may also be promoted by MAPK inhibition. BRAFi was found to increase T cell activity such as IFNɣ release in BRAF-mutant melanoma cells [21, 26] . Furthermore, treatment of patients with BRAF-mutant melanoma with either BRAFi +/-MEKi was associated with an increase in perforin and ↑ production of granzyme B, IFNγ and TNFα [49] ↑ increased ↓ reduced → no effect. granzyme B, which are markers of T cell cytotoxicity [37] . Enhanced IFNɣ release of T cells was also observed with MEKi when co-cultured with BRAF wild-type cells [21] .
In summary (Table 1) , in addition to having no adverse effects on host immune cells in vivo (as described in section 2), BRAFi +/-MEKi might also enhance the reactivity and cytotoxicity of T cells in BRAFmutant and wild-type melanoma.
Synergistic effects of combining MAPK inhibitors with immune checkpoint inhibitors (preclinical data)
The immunological effects of BRAFi and MEKi leading to enhanced antitumor T cell responses in BRAF-mutant and wild-type melanoma (as detailed in section 4) provide a rationale for combining targeted therapy with immune checkpoint inhibitors in order to achieve superior response rates and increased duration of response. Preclinical studies support this hypothesis.
Combination of BRAFi +/-MEKi with immune checkpoint inhibitors in BRAF mutated melanoma
A series of in vivo experiments with oncogenic BRAF melanoma [19, 43, 49 ] detected a superior antitumor activity of BRAFi +/-MEKi in combination with immune checkpoint inhibitors compared to the antitumor activity of BRAFi and MEKi or immune checkpoint inhibitors alone ( Table 2) .
In a BRAFV600E/PTEN −/− immunocompetent mouse model, combining BRAFi with immune checkpoint inhibitors versus BRAFi alone increased the number of TILs, led to a decreased tumor volume, enhanced therapy response and significantly prolonged survival [43] . In a mouse model of syngeneic BRAFV600E-driven melanoma, combination of dabrafenib and trametinib with pmel-1 ACT showed increased T cell infiltration into tumors, enhanced cytotoxicity and achieved superior antitumor effects compared to ACT combined with the single agents dabrafenib or trametinib [19] . Dabrafenib alone increased tumor-associated macrophages and Tregs in the tumors, which decreased with the addition of trametinib. Furthermore, the triple combination of dabrafenib, trametinib and anti-PD1 provided the highest antitumor activity compared with any other double combination, strongly supporting the rationale for combining BRAFi and MEKi with immunotherapy in patients with BRAFmutant metastatic melanoma.
Combination of MEKi with immune checkpoint inhibitors in BRAF wildtype melanoma
In a KRAS-mutant CT26 colorectal tumor syngeneic mouse model (BRAF wild-type) combining the MEKi trametinib with different immune checkpoint inhibitors was more effective in tumor control than any single agent [22] . Trametinib alone and in combination with the anti-PD-1 antibody, but not the anti-PD-1 antibody alone, significantly increased frequencies of CD4 + T cells in the tumor. Only the combination of trametinib and anti-PD-1 antibody significantly increased frequencies of CD8 + T cells in the tumor. Moreover, CD69 + /CD8 + cells were reduced by 57% in the combination treatment compared to the untreated control. Tumor gene expression profiling revealed that trametinib alone and even more so trametinib in combination with anti-PD-1 downregulated immunosuppressive factors and upregulated HLA class II molecules compared to the untreated control. Together (Table 2) , these data support the rationale of combining MEKi with immune checkpoint inhibitors in BRAF wild-type melanoma.
Time of progression on BRAFi/MEKi-therapy: changes in immunogenic profiles
Current data suggest that BRAFi/MEKi have a positive impact on the immune response early in the course of therapy that wanes at time of Table 4 Combination immunotherapy and targeted therapy: First results of clinical trials. progression. Resistance to targeted therapy may occur through genetic and epigenetic alterations [51, 52] . Intriguingly, Song et al. showed that changes in the transcriptome arose early during BRAFi treatment response and were characterized by a mesenchymal-angiogenic switch and an increased expression of multiple receptor tyrosine kinases in melanoma cells and patient-tumors [51] . At time of progression, PD-L2 was up-regulated in both melanoma cells and tumor-infiltrating immune cells and promoted loss of CD8 + T cell inflammation. Interestingly, blockage of PD-L2 increased CD8 + T cell infiltration and prolonged BRAFi response.
Other studies in mouse models and human tumor tissue also showed that BRAFi +/-MEKi treatment at time of progression was associated with a decrease in CD8 + T cell infiltration and/or in the ratio of CD8 + T cells to Tregs [37, 43, 53, 54] . Furthermore, with BRAFi therapy the CD4 + T cell infiltration diminished at the time of progression [45] .
Monotherapy with BRAFi was associated with decreased melanoma antigen expression such as MART1, TYRP1, DCT or gp100 at time of progression, which may reduce the recognition of the tumor by T cells. This effect was reversed with combined BRAF and MEK inhibition [37] . Furthermore, there was an increase in the expression of T cell exhaustion markers including PD-1 and TIM-3 on infiltrating T cells, and the immunosuppressive ligand PD-L1 and PD-L2 on tumor cells within 10-14 days of BRAFi initiation, suggesting that immune checkpoint blockade may enhance responses to BRAFi -/+ MEKi [37, 43] .
Kakavand et al. analyzed patient tumors treated with BRAFi alone or in combination with MEKi at different time points: at baseline, early during treatment and at time of progression [55] . Intriguingly, tumors that were PD-L1 positive at baseline showed a decrease in PD-L1 expression during treatment and at progression, whereas tumors that were PD-L1 negative at baseline showed an increase in PD-L1 expression over time. This observation strongly correlated with TIL immune markers. PD-L1 expression levels at different time points may thus inform whether a patient would benefit from concurrent or sequential MAPK inhibitor and immune checkpoint inhibitor therapy.
Taken together, these observations (Table 3) imply that the immunostimulatory effects observed with treatment response may subside at disease progression. The low CD8 + T cell density and expression of T cell exhaustion markers at progression may be one reason why immune checkpoint inhibitors are less effective after failure of BRAF inhibitor therapy. These results are particularly important in terms of finding the most effective therapy sequence when BRAFi and MEKi are combined with immune checkpoint inhibitors. The immune checkpoint inhibitors may enhance responses to BRAFi -/+ MEKi especially in patients with low PD-L1 expression at baseline.
Combination targeted therapy and immunotherapy: ongoing clinical trials and first results
Early data from phase I clinical trials that combine targeted therapy with immunotherapy suggest that overall response rates (ORR) of triple-combination (immunotherapy, BRAFi and MEKi) therapies may be similar or even higher compared to combined BRAFi and MEKi therapy alone. Although toxicity of triple-combination therapies, in particular grade ≥ 3 toxicity, appears to be higher compared to BRAFi/ (OS = overall survival; PFS = progression-free survival).
M. Kuske et al. Pharmacological Research 136 (2018) [151] [152] [153] [154] [155] [156] [157] [158] [159] MEKi combinations, toxicity appears to be manageable. By contrast, toxicity of combinations of BRAFi/MEKi with anti-CTLA-4 antibodies is not acceptable. For example, a phase I trial featuring combination treatment with vemurafenib and ipilimumab was terminated due to hepatotoxicity [56] [57] [58] . Table 4 summarizes the available data of these triple-combination trials. The optimal sequence of BRAFi/MEKi and immune checkpoint inhibitor treatment is a highly relevant question, which remains unanswered so far. As already discussed in this and the previous section, the higher toxicity of triple combinations may be a limiting factor. Given the positive immunological effects of MAPKi treatment including the increase in PD-L1 expression in melanoma cells, one could envision a sequence of BRAFi/MEKi treatment followed by immunotherapy. So far, it is unknown how long the run-in phase of BRAFi/MEKi should be to avoid that the immunological effects of BRAFi/MEKi subside. There are several ongoing clinical trials that investigate the combination of BRAFi/MEKi with immune checkpoint inhibitors, in particular with anti-PD-1 or anti-PD-L1, to determine the optimal treatment strategy and also the best sequence of treatment ( Table 5 ). The results of these studies are eagerly awaited.
Conclusion
The available data indicate that BRAFi/MEKi have favorable effects on antitumor immunity, which are mediated by a variety of different mechanisms. The favorable immune effects, however, are paralleled by the induction of T cell exhaustion markers, and the immunostimulatory effects observed with treatment response appear to subside over time. Taken together, these data provide a strong rationale for combination strategies with BRAFi/MEKi and immune checkpoint inhibitors. There are still many unanswered questions relating to combination regimens, toxicity and optimal timing or sequencing. Current and future clinical trials are addressing these questions. In addition to clinical trials, accompanying translational studies with longitudinal tissue and blood analyses and preclinical studies are highly relevant to understand and overcome mechanisms of therapy resistance. Designing the optimal treatment of individual patients can only be achieved through the joint effort of scientists and clinicians.
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